Gapping up
In reaction to earnings/guidance:
- SMTC +21.7%, REVG +18.7%, DBI +5.3%, TCOM +4%, VRNT +3.7%, GEF +2.2%
Other news:
- FDMT +11.7% (presents interim data from Phase 1/2 AEROW trial)
- EXPI +9% (to join S&P Small Cap 600)
- IPHA +6.3% (SAR'579 / IPH6101 receives FDA Fast Track Designation in the US for the treatment of hematological malignancies)
- PRVA +5.3% (to join S&P Small Cap 600)
- UHT +5.2% (increases dividend)
- RCEL +4.3% (receives FDA approval for RECELL for treatment of full-thickness skin defects)
- HP +3.1% (increases share repurchase authorization in FY23)
- ALV +3% (accelerates structural cost reductions; reiterates its full year 2023 indications)
- WHD +1.5% (authorizes $150 mln stock repurchase program)
- BLBD +1% (prices secondary offering of 4.5 mln shares of common stock at $20.00 per share)
- AFRM +1% (authorized the repurchase of up to $800 million in aggregate principal amount of its outstanding 0% Convertible Senior Notes due 2026)
Analyst comments:
- EVO +9.2% (upgraded to Buy from Neutral at Citigroup)
- AMZN +1% (initiated with an Overweight at Wells Fargo)